156 related articles for article (PubMed ID: 15987071)
1. [The future of pharmacogenetics--cost-effectiveness and barriers].
Gyrd-Hansen D
Ugeskr Laeger; 2005 May; 167(20):2153-5. PubMed ID: 15987071
[No Abstract] [Full Text] [Related]
2. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
3. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
4. The role of innovation in drug development.
Drews J; Ryser S
Nat Biotechnol; 1997 Dec; 15(13):1318-9. PubMed ID: 9415870
[No Abstract] [Full Text] [Related]
5. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
6. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
Chalkidou K; Rawlins M
Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
[TBL] [Abstract][Full Text] [Related]
7. Economic and developmental considerations for pharmacogenomic technology.
Vernon JA; Johnson SJ; Hughen WK; Trujillo A
Pharmacoeconomics; 2006; 24(4):335-43. PubMed ID: 16605280
[TBL] [Abstract][Full Text] [Related]
8. Genomic sciences and the medicine of tomorrow.
Drews J
Nat Biotechnol; 1996 Nov; 14(11):1516-8. PubMed ID: 9634812
[No Abstract] [Full Text] [Related]
9. Creating incentives for genomic research to improve targeting of therapies.
Evans BJ; Flockhart DA; Meslin EM
Nat Med; 2004 Dec; 10(12):1289-91. PubMed ID: 15580246
[No Abstract] [Full Text] [Related]
10. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
11. Practical considerations for pharmacogenetic testing.
Wedlund PJ
MLO Med Lab Obs; 2001 Sep; 33(9):16-21, 23; quiz 24-5. PubMed ID: 11569125
[No Abstract] [Full Text] [Related]
12. Biotech's billion dollar breakthrough.
Stipp D
Fortune; 2003 May; 147(10):96-8, 100, 103. PubMed ID: 12776500
[No Abstract] [Full Text] [Related]
13. Can personalized drugs pay off?
Stipp D
Fortune; 2002 May; 145(10):168. PubMed ID: 12025349
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics--where are we and where are we heading?
Kola I
Pharmacogenomics; 2005 Dec; 6(8):793-5. PubMed ID: 16296941
[No Abstract] [Full Text] [Related]
15. Ethical, social and legal issues in pharmacogenomics.
Wertz DC
Pharmacogenomics J; 2003; 3(4):194-6. PubMed ID: 12931132
[No Abstract] [Full Text] [Related]
16. Biotech drugs come of age; policymakers take notice.
Iglehart JK
Health Aff (Millwood); 2006; 25(5):1202-3. PubMed ID: 16966714
[No Abstract] [Full Text] [Related]
17. Pharmacogenomics: questions and concerns.
Mahlknecht U; Voelter-Mahlknecht S
Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics: an assessment of market conditions and competition.
Grimaldi BA
Find Brief; 2007 Mar; 10(3):1-4. PubMed ID: 17354334
[No Abstract] [Full Text] [Related]
19. The DNA Rx. Advances in genetics give physicians ability to tailor drugs to patients' unique makeup.
Becker C
Mod Healthc; 2000 Aug; 30(36):24-8, 30, 33. PubMed ID: 11186365
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry].
Hansen L; Andersen D
Ugeskr Laeger; 2005 May; 167(20):2160-4. PubMed ID: 15987073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
